

- adenocarcinoma of the pancreatic head. *J Clin Oncol* 26 : 3487–3495, 2008
- 27) Small W Jr, Berlin J, Freedman GM et al : Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. *J Clin Oncol* 26 : 942–947, 2008
- 28) Le Scodan R, Mornex F, Girard N et al : Preoperative chemoradiation in potentially resectable pancreatic adenocarcinoma: feasibility, treatment effect evaluation and prognostic factors, analysis of the SFRO-FFCD 9704 trial and literature review. *Ann Oncol* 20 : 1387–1396, 2009
- 29) Ohigashi H, Ishikawa O, Eguchi H et al : Feasibility and efficacy of combination therapy with preoperative full-dose gemcitabine, concurrent three-dimensional conformal radiation, surgery, and postoperative liver perfusion chemotherapy for T3-pancreatic cancer. *Ann Surg* 250 : 88–95, 2009
- 30) Landry J, Catalano PJ, Staley C et al : Randomized phase II study of gemcitabine plus radiotherapy versus gemcitabine, 5-fluorouracil, and cisplatin followed by radiotherapy and 5-fluorouracil for patients with locally advanced, potentially resectable pancreatic adenocarcinoma. *J Surg Oncol* 101 : 587–592, 2010
- 31) Turrini O, Ychou M, Moureau-Zabotto L et al : Neo-adjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response. *Eur J Surg Oncol* 36 : 987–992, 2010
- 32) Takahashi H, Ohigashi H, Gotoh K et al : Preoperative gemcitabine-based chemoradiation therapy for resectable and borderline resectable pancreatic cancer. *Ann Surg* 258 : 1040–1050, 2013
- 33) Doi R, Imamura M, Hosotani R et al : Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial. *Surg Today* 38 : 1021–1028, 2008

\*

\*

\*

